CN1126564C - 葡萄提取物的膦脂复合物作为抗动脉粥样硬化剂的应用 - Google Patents

葡萄提取物的膦脂复合物作为抗动脉粥样硬化剂的应用 Download PDF

Info

Publication number
CN1126564C
CN1126564C CN98811768A CN98811768A CN1126564C CN 1126564 C CN1126564 C CN 1126564C CN 98811768 A CN98811768 A CN 98811768A CN 98811768 A CN98811768 A CN 98811768A CN 1126564 C CN1126564 C CN 1126564C
Authority
CN
China
Prior art keywords
extracts
application
vitis viniferae
fructus vitis
vitis vinifera
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN98811768A
Other languages
English (en)
Other versions
CN1280498A (zh
Inventor
P·默拉佐尼
E·博姆巴戴利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indena SpA
Original Assignee
Indena SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indena SpA filed Critical Indena SpA
Publication of CN1280498A publication Critical patent/CN1280498A/zh
Application granted granted Critical
Publication of CN1126564C publication Critical patent/CN1126564C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E50/00—Technologies for the production of fuel of non-fossil origin
    • Y02E50/30—Fuel from waste, e.g. synthetic alcohol or diesel

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Solid Fuels And Fuel-Associated Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

葡萄提取物的磷脂复合物适用于预防和治动脉粥样硬化的病理状态。

Description

葡萄提取物的磷脂复合物 作为抗动脉粥样硬化剂的应用
本发明涉及从葡萄提取的、含2～7个儿茶素单元的寡聚原花色素的磷脂复合物在制备用于治疗和预防动脉粥样硬化以及心肌梗死和脑梗塞的药剂方面的应用。
已知葡萄提取物可用于治疗与静脉功能不全相关的心血管病，用于治疗毛细渗透性和抗性降低的疾病以及结瘢。如GB-A-1,541,469或FR-A-2,092,743中所述，这些提取物(它们可得自该植物的籽)是多酚(例如表儿茶素)及其聚合产物(该单体的C-3羟基部分地用棓酸酯化了)的混合物。葡萄提取物的磷脂复合物被描述于US-4,963,527中，现在可以以商标Leucoselect商购。
现已意外地发现了，当系统施药(优选通过经口途径)时，按US-4,963,527制备的复合物在动物和人中都产生显著的抗动脉粥样硬化的活性。
更具体地说，发现了从葡萄提取的、含2～7个儿茶素单元的寡聚原花色素的磷脂复合物能以剂量依存关系预防或减少动脉粥样斑块的形成。
这种活性在喂食高胆固醇血的食物(为的是在血管水平，尤其在弓动脉、腹主动脉、颈动脉和脑血管中引起类似于人那样的动脉粥样病斑)的兔中得到了证实。在所述模型中，上述磷脂复合物改变了宏观和微观血管状态，与未处理的动物相比，既减少了动脉粥样斑块的数量又降低了它们的严重程度，获得意外的血管组织效益。在另一动脉粥样硬化模型(为了保护脑)中(其中，通过手术减小了兔颈动脉内的血管腔)，随着喂食富含饱和脂肪的高胆固醇血的食物，表现出颈动脉梗阻的减轻、血管壁厚度的减小和动物存活率的增大。此外，在动脉粥样硬化患者中，通过多普勒超声波扫描术鉴定，观测到因动脉粥样化斑引起的颈动脉梗阻的减轻和颈动脉流的改善。
从葡萄提取的原花色素的磷脂复合物可以合适的口服制剂(例如片剂、软或硬明胶胶囊)在50～500mg(每天二至三次)的剂量范围(取决于受治疗的疾病的严重程度)应用。药物制剂的制备可按常规技术和赋形剂进行。
如下实施例更详细地阐述了本发明。
                     实施例1
3组(每组8只)新西兰兔接受下列处理：1)组：对比组，正常食物2)组：高胆固醇血的食物(0.2％胆固醇)3)组：高胆固醇血的食物+葡萄提取物的磷脂复合物(0.2％胆固醇+2％
  Leucoselect(R))。
8周(在此期间测定胆固醇、LDL/VLDL、HDL和甘油三酯含量)后，杀死这些动物。
估测胸主动脉和腹主动脉上动脉粥样硬化损害的数量、尺寸和分布。
固定主动脉条并用苏丹IV染色(以便观察损害)，通过气相色谱法估测血管胆固醇和氧化的胆固醇含量。
下表中报导的结果证明了，用葡萄提取物的磷脂复合物处理以统计上显著的方式减少了由高胆固醇血的食物引起的动脉粥样硬化损害。
表处理                                 损害的面积百分数1组                                          1％2组                                          27％3组                                          5％* *p＜0.01，与2组相比
                        实施例2含500mg葡萄提取物的磷脂复合物的胶囊组成：
葡萄提取物的复合物
(含大豆磷脂酰胆碱)                            200mg
乳糖                                          57mg
改性淀粉                                      40mg
硬脂酸镁                                      3,0mg
                       实施例3
耐胃的(gastro-resistant)片剂
葡萄提取物的复合物
(含大豆磷脂酰胆碱)                                 250mg
微晶纤维素                                         118mg
沉淀二氧化硅                                       3mg
硬脂酸镁                                           4mg
甲基丙烯酸阴离子聚合物及其酯                       12mg
滑石粉                                             8mg
碳酸镁                                             8mg
玉米淀粉                                           5mg
阿拉伯树胶                                         159mg
                         实施例4
软明胶胶囊
葡萄提取物的复合物
(含大豆磷脂酰胆碱)                                 266mg
花生油                                             209mg
部分氢化的植物油                                   100mg
大豆卵磷脂                                         5mg

Claims (4)

1.从葡萄提取的、含2～7个儿茶素单元的寡聚原花色素的磷脂复合物在制备用于治疗和预防动脉粥样硬化以及心肌梗死和脑梗塞的药剂方面的应用。
2.如权利要求1的应用，其中，所述药剂的单元剂量在50～500mg活性成分的范围内。
3.权利要求1或2的应用，其中，所述药剂被经口给药。
4.权利要求3的应用，其中，所述药剂呈软或硬明胶胶囊或者片剂的形式。
CN98811768A 1997-12-04 1998-11-30 葡萄提取物的膦脂复合物作为抗动脉粥样硬化剂的应用 Expired - Fee Related CN1126564C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI97A002690 1997-12-04
IT97MI002690A IT1296920B1 (it) 1997-12-04 1997-12-04 Uso di complessi di estratti vitis vinifera con fosfolipidi come agenti anti-aterosclerotici

Publications (2)

Publication Number Publication Date
CN1280498A CN1280498A (zh) 2001-01-17
CN1126564C true CN1126564C (zh) 2003-11-05

Family

ID=11378312

Family Applications (1)

Application Number Title Priority Date Filing Date
CN98811768A Expired - Fee Related CN1126564C (zh) 1997-12-04 1998-11-30 葡萄提取物的膦脂复合物作为抗动脉粥样硬化剂的应用

Country Status (23)

Country Link
US (1) US6297218B1 (zh)
EP (1) EP1035859B1 (zh)
JP (1) JP4456267B2 (zh)
KR (1) KR100567867B1 (zh)
CN (1) CN1126564C (zh)
AT (1) ATE258802T1 (zh)
AU (1) AU743031B2 (zh)
BR (1) BR9805813B1 (zh)
CA (1) CA2312795C (zh)
CZ (1) CZ299555B6 (zh)
DE (1) DE69821524T2 (zh)
DK (1) DK1035859T3 (zh)
ES (1) ES2214755T3 (zh)
HK (1) HK1033267A1 (zh)
HU (1) HU228109B1 (zh)
IT (1) IT1296920B1 (zh)
NO (1) NO324796B1 (zh)
PL (1) PL191023B1 (zh)
PT (1) PT1035859E (zh)
RU (1) RU2207866C2 (zh)
SI (1) SI1035859T1 (zh)
SK (1) SK284865B6 (zh)
WO (1) WO1999029331A1 (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1304183B1 (it) 1998-12-18 2001-03-08 Indena Spa Complessi di proantocianidina a2 con fosfolipidi come agentiantiaterosclerotici.
JP2001122791A (ja) * 1999-10-20 2001-05-08 Boehringer Ingelheim Internatl Gmbh 下肢の慢性静脈不全の軽減および予防のための赤色ブドウ樹葉の水性抽出物よりなる食事補強剤
JP4574788B2 (ja) 2000-03-24 2010-11-04 協和発酵バイオ株式会社 プロアントシアニジン含有組成物
IT1320080B1 (it) * 2000-10-25 2003-11-18 Giuliani Spa Composizione per uso farmaceutico o dietetico.
FR2836337B1 (fr) * 2002-02-28 2004-11-19 Bio Serae Laboratoires Utilisation des polymeres procyanidoliques a titre d'agents inhibuteurs des alpha-amylases et application dans des compositions a visees dietetiques
US20040151769A1 (en) * 2002-12-31 2004-08-05 Boehringer Ingelheim International Gmbh Film coated tablet containing an extract of red vine leaves
DE60332767D1 (de) * 2002-12-31 2010-07-08 Boehringer Ingelheim Int Filmtablette mit extrakt aus roten weinblättern
ITMI20031313A1 (it) * 2003-06-27 2004-12-28 Indena Spa Associazioni di agenti vasoprotettori e formulazioni che li contengono.
EP1550450A1 (en) * 2003-12-29 2005-07-06 Boehringer Ingelheim International GmbH Composition comprising an aqueous extract of red vine leaves and a blood circulating-improving agent for the treatment of chronic venous insufficiencies
BRPI0507895A (pt) 2004-02-19 2007-07-24 Boehringer Ingelheim Int composição para o tratamento de insuficiências venosas crÈnicas, compreendendo um extrato de folhas de videira-vermelha e um agente antiinflamatório
US20060088617A1 (en) * 2004-10-23 2006-04-27 Mccurry James M Chocolate composition and method for benefiting the cardiovascular system
AT501682A1 (de) 2005-01-14 2006-10-15 Hermine Dr Engl Verfahren zur herstellung einer wirkstoffmischung
EP1837030A1 (en) 2006-03-09 2007-09-26 INDENA S.p.A. Phospholipid complexes of curcumin having improved bioavailability
EP2829277A1 (en) 2013-07-26 2015-01-28 Natac Biotech, S.L. Use of a-type proanthocyanidins in treating a mineralocorticoid receptor related disease
WO2019087084A1 (en) 2017-11-02 2019-05-09 Eman Biodiscoveries Sd. Bhd. Extract of orthosiphon stamineus, formulations, and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2092743A1 (en) * 1970-06-15 1972-01-28 Aquitaine Invest Pharma Complete extraction of total flavanol gomers from plats -peripheral - venous activity
GB1541469A (en) * 1976-12-01 1979-02-28 Inverni Della Beffa Spa Method of obtaining flavonolic oligomers
IT1201151B (it) * 1987-01-14 1989-01-27 Indena Spa Complessi fosfolipidici con estratti da vitis vinifera,procedimento per la loro preparazione e composizioni che li cntengono
US5484594A (en) * 1988-06-28 1996-01-16 Tecnofarmaci S.P.A. Process for preparing grapeseed extracts enriched in procyanidol oligomers
FI955691A (fi) 1994-11-28 1996-05-29 Suntory Ltd Lipoproteiini(a):ta alentava aine, kolesterolia alentava aine ja näitä aineita sisältävät lääkkeet

Also Published As

Publication number Publication date
HUP0100522A3 (en) 2002-04-29
AU743031B2 (en) 2002-01-17
KR100567867B1 (ko) 2006-04-04
DE69821524T2 (de) 2005-01-05
PL191023B1 (pl) 2006-03-31
HU228109B1 (en) 2012-11-28
NO324796B1 (no) 2007-12-10
WO1999029331A1 (en) 1999-06-17
ITMI972690A1 (it) 1999-06-04
HUP0100522A2 (hu) 2001-12-28
ATE258802T1 (de) 2004-02-15
KR20010024654A (ko) 2001-03-26
IT1296920B1 (it) 1999-08-03
US6297218B1 (en) 2001-10-02
JP4456267B2 (ja) 2010-04-28
EP1035859A1 (en) 2000-09-20
BR9805813A (pt) 1999-12-14
SK284865B6 (sk) 2006-01-05
ES2214755T3 (es) 2004-09-16
NO20002827L (no) 2000-06-02
CZ299555B6 (cs) 2008-09-03
NO20002827D0 (no) 2000-06-02
PL340884A1 (en) 2001-03-12
CN1280498A (zh) 2001-01-17
SK8272000A3 (en) 2000-11-07
PT1035859E (pt) 2004-05-31
JP2001525370A (ja) 2001-12-11
DE69821524D1 (de) 2004-03-11
SI1035859T1 (en) 2004-04-30
CZ20002038A3 (cs) 2000-12-13
HK1033267A1 (en) 2001-08-24
RU2207866C2 (ru) 2003-07-10
CA2312795A1 (en) 1999-06-17
BR9805813B1 (pt) 2009-05-05
EP1035859B1 (en) 2004-02-04
CA2312795C (en) 2009-01-20
AU1562799A (en) 1999-06-28
DK1035859T3 (da) 2004-05-17

Similar Documents

Publication Publication Date Title
CN1126564C (zh) 葡萄提取物的膦脂复合物作为抗动脉粥样硬化剂的应用
KR101809172B1 (ko) 뮤신이 없는 배지에서 배양한 아커만시아 뮤시니필라 균주 또는 이의 배양액을 유효성분으로 함유하는 대사성 질환의 예방, 개선 또는 치료용 조성물
US8017162B2 (en) Anti-inflammatory agent
US20100098786A1 (en) Formulation containing a carboxylic acid or an ester thereof
SK10802001A3 (sk) Esenciálne mastné kyseliny na prevenciu kardiovaskulárnych príhod
PH26694A (en) Mixtures for treating hyper-cholesterolemia
JPH09165331A (ja) レスベラトロールまたはその誘導体を併用するｌ−カルニチンまたはアルカノイル ｌ−カルニチン含有医薬組成物
ES2340510T3 (es) Uso de alquil-furanos para la preparacion de un medicamento destinado al tratamiento de la obesidad y para el tratamiento cosmetico del exceeso de peso.
US20100173856A1 (en) Methods of producing and using nutritional and pharmaceutical compositions that include one or more active substances
US10967027B2 (en) Extracts of Cyclanthera pedata and formulations and uses thereof
WO2001085164A1 (en) The treatment of herpes
CN102309004A (zh) 一种降胆固醇的功能性保健食品
JP4629834B2 (ja) 神経細胞賦活剤およびその利用
KR100416650B1 (ko) 둥굴레 추출물과 그를 함유한 혈장 지질 및 혈당 강하용조성물
JP4852296B2 (ja) 血管炎症候群予防・治療剤
KR100662903B1 (ko) 글루코사민 하이드로클로라이드를 함유하는 당뇨 질환치료용 의약 조성물
JP4913289B2 (ja) カスパーゼ阻害剤
JPH09187248A (ja) 抗アレルギー食品
CA2504280A1 (en) Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease
WO2001024805A1 (en) Composition with lipid-lowering activity
RU2292902C2 (ru) Средство "литохол" и способ поддерживающей терапии при нарушении обмена веществ, вызванном повышенным содержанием холестерина в крови
US20200376003A1 (en) Pharmaceutical composition for preventing or treating cholesterol gallstone comprising ursodeoxycholic acid (udca) and omega-3 fatty acid, and process for producing the same
EP1702615A1 (en) Glucose tolerance-improving agent
EP0803202A2 (en) Dietary composition containing chitosan, Garcinia cambogia hydroxycitrate and organic chromium
JPS6011421A (ja) 血中脂質降下剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20031105

Termination date: 20131130